^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    LRRC32 inhibitor

    Related drugs:
    Associations

    News

    Trials
    4ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    4ms
    LIVIGNO-3: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    4ms
    A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=12, Recruiting, Pure Biologics S.A. | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma. (PubMed, Leukemia)
    DS-1055a, an anti-GARP monoclonal antibody, selectively and effectively depleted malignant ATL cells via antibody-dependent cellular cytotoxicity, supporting the proof-of-concept in the preclinical study. Our findings highlight the key to understanding the cell origin of ATL and developing unprecedented therapeutic strategies for refractory diseases.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    7ms
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=364, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    8ms
    A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    9ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2/3, N=660, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    12ms
    Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
    P2, N=150, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Metastases
    |
    gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    1year
    A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Pure Biologics S.A.
    New P1 trial
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    1year
    A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    1year
    Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, AbbVie
    New P2 trial
    |
    gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    1year
    LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
    |
    sorafenib • Lenvima (lenvatinib) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)